GRIDtoday Logo Altair

DAILY NEWS AND INFORMATION FOR THE GLOBAL GRID COMMUNITY / APRIL 7, 2003: VOL. 2 NO. 14

( Previous Article )   ( Table of Contents )   ( Next Article )

Scientific Applications:

AVAKI DATA GRID TO SUPPORT BIOFORMATICS RESEARCH

The global pharmaceutical company, Aventis, has decided to choose Avaki Corporation for their Avaki Data Grid software. This software will provide automated, secure, wide-area access to bioinformatics research data across multiple North American research sites.

Avaki software will enable users to share important research data without the need to manually compress and copy data files by making data available to multiple sites and administrative domains from its source location. This approach can help to eliminate data inconsistency and synchronization challenges associated with multiple copies, and to prevent unnecessary consumption of disk space and productivity delays.

Using the Avaki Data Grid, data can be shared securely and seamlessly among geographically dispersed users and applications, with automated access to wide-area data that appears local to those who have been granted access to it.

The Grid software ensures the consistency of data across the organization, ensures access to the most current data available, and provides a uniform environment that is easy for researchers to use and for IT professionals to administer.

Tim Yeaton, President of Avaki said, "Life sciences organizations demand the ability to quickly and easily access huge amounts of data, regardless of where it resides, and securely share it in a timely and consistent fashion across their R&D teams." Yeaton went on to say, "The Avaki Data Grid solution has been particularly appealing to life sciences organizations because of its unique ability to address the data-intensive work that drives the business processes of these organizations. We are extremely pleased to make this solution available to Aventis."

Web site: www.avaki.com

( Top of Page )

( Previous Article )   ( Table of Contents )   ( Next Article )